Welcome to our dedicated page for Entero Therapeutics SEC filings (Ticker: ENTO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Entero Therapeutics, Inc. (NASDAQ: ENTO) SEC filings page on Stock Titan aggregates the company’s regulatory disclosures from the U.S. Securities and Exchange Commission, including Forms 10-K, 10-Q, 8-K, registration statements, and other required reports. These documents provide detailed information on Entero’s dual focus: late clinical-stage development of targeted, non-systemic therapies for gastrointestinal diseases and the integration of Grid AI, a grid-edge, AI-driven software and device platform.
In its S-1/A registration statement, Entero outlines its GI pipeline and describes Adrulipase as a recombinant lipase enzyme for exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis. The same filing explains that the company is a smaller reporting company with common stock listed on the Nasdaq Capital Market under the symbol ENTO. Investors can use annual reports on Form 10-K and quarterly reports on Form 10-Q, when filed, to review research and development activities, risk factors, and financial statements.
Recent Forms 8-K are particularly important for understanding Entero’s corporate transition. One 8-K details the share exchange agreement through which Entero acquired 100% of Grid AI Corp, issuing common and Series H non-voting convertible preferred stock and granting Grid AI shareholders the right, subject to conditions, to designate a majority of directors. Other 8-K filings describe Nasdaq correspondence regarding compliance with Listing Rule 5550(b)(1), a Securities Purchase Agreement for a promissory note and warrant financing, and governance arrangements related to Grid AI’s shareholders and board representation.
A Form 12b-25 (NT 10-Q) explains that Entero requested additional time to file a quarterly report due to the complexity of accounting for the Grid AI acquisition. Together, these filings allow investors to track equity structure, financing arrangements, listing compliance, and the accounting treatment of major transactions. On Stock Titan, AI-powered tools summarize lengthy documents such as 10-Ks, 10-Qs, and 8-Ks, highlight key terms in registration statements like the S-1/A, and help surface notable items in ownership and governance disclosures, so readers can more quickly interpret ENTO’s regulatory history and ongoing obligations.
GridAI Technologies Corp. filed its annual report outlining a strategic shift into AI-focused energy orchestration software while retaining its Adrulipase drug program. The company acquired Grid AI Corp. and 75% of AMPX, rebranded from Entero Therapeutics, and now centers on software for AI data centers and legacy biopharma R&D.
Grid AI’s platforms are early stage with minimal revenue and no commercial deployment yet for its AI data center solution. Adrulipase remains the main drug asset but had no active trials in 2025. At December 31, 2025, cash was about $0.9 million against an accumulated deficit of roughly $208.8 million, and auditors raised substantial doubt about continuing as a going concern.
The company defaulted on an 18% revolving loan and is exploring strategic alternatives, including potential merger, sale, wind-down or bankruptcy, while also managing past and current Nasdaq listing compliance issues. Only two parent-level employees remain, underscoring the scale-back as GridAI pursues a high-risk turnaround around its AI energy orchestration platform.
GridAI Technologies Corp. reported receiving a notice from Nasdaq on April 22, 2026 stating it is not in compliance with Listing Rule 5250(c)(1) because its Form 10-K for the year ended December 31, 2025 has not yet been filed. The company has until June 22, 2026 to submit a plan to regain compliance, and Nasdaq may grant an extension through October 12, 2026 if the plan is accepted. GridAI attributes the delay to complexity in reviewing the accounting treatment and other information related to its recent acquisition of Grid AI Corp. The company plans to file the 10-K as soon as possible and submit a compliance plan, but cautions there is no assurance Nasdaq will accept the plan or that it will maintain compliance with Nasdaq requirements in the future.
GridAI Technologies Corp. reports a default-related demand under its Revolving Loan Agreement. The company’s lender sent a demand letter on April 1, 2026, asserting that the loan matured unpaid on January 31, 2026, and seeking $1,014,675, including $700,000 principal, accrued interest, and a 20% default increase. GridAI is evaluating the impact and is in active discussions with the lender.
GridAI Technologies Corp. filed an amended report to provide full historical financials, pro forma results, business description, and risk factors for its acquisition of Grid AI Corp. Grid AI generated only $138,697 of revenue from inception through September 30, 2025 but recorded a net loss of $5,251,751 and a total deficit of $6,521,829. The auditor and management both highlight substantial doubt about Grid AI’s ability to continue as a going concern, citing limited cash of about $333,000, negative working capital, and significant obligations including $7,000,000 of deferred consideration. Pro forma for the acquisition, the combined company reports a net loss of $10,589,048 for the period ended September 30, 2025. The filing also describes a strategic pivot away from legacy residential energy platforms toward an early-stage AI data center energy orchestration platform that has not yet been commercially deployed, along with extensive competitive and execution risks.
GridAI Technologies Corp. received a Schedule 13G/A filing from Renaissance Technologies LLC and Renaissance Technologies Holdings Corporation reporting a passive ownership position. The reporting persons beneficially own 31,000 shares of common stock, representing 0.92% of the class as of 12/31/2025.
Renaissance reports sole voting and dispositive power over these shares and confirms they are held in the ordinary course of business, not for the purpose of changing or influencing control of GridAI. Certain funds managed by Renaissance Technologies LLC have the right to receive dividends and sale proceeds from these securities.
GridAI Technologies Corp. received a new Schedule 13G disclosure showing that Strategic EP, LLC and Alexander Chase Deitch together report beneficial ownership of 209,541 shares of common stock, representing 5.0% of the company’s outstanding shares. This percentage is based on 4,162,695 shares outstanding as of the date of the statement. The filing states the investors share voting and dispositive power over these shares and classify themselves as passive holders, certifying that the position was acquired and is held in the ordinary course of business and not for the purpose of changing or influencing control. They also hold warrants and pre-funded warrants subject to 4.99% or 9.99% beneficial ownership limits, so the underlying shares are excluded from the reported ownership.
GridAI Technologies Corp. director Edward Borkowski reported a stock grant. On January 1, 2026, he was awarded 40,000 restricted stock units that will be settled in shares of common stock with a par value of $0.0001 per share. The filing states these restricted stock units vested immediately upon issuance on January 1, 2026. Following this grant, Borkowski beneficially owns 60,248 shares of common stock directly.
GridAI Technologies Corp. completed a previously agreed rescission transaction involving ImmunogenX, LLC on December 31, 2025. Under this deal, the company transferred to the former ImmunogenX, Inc. shareholders all of the membership interests of ImmunogenX, LLC that it held, so ImmunogenX, LLC is no longer a subsidiary and the company no longer owns any interest in it.
The company notes that this disposition is considered a significant asset sale for reporting purposes, and it has filed unaudited pro forma consolidated financial statements as an exhibit to show how the transaction would have affected its historical financials.
Entero Therapeutics, Inc. reported a Q3 2025 net loss of $1,152,809, improving from $2,580,971 a year earlier as operating expenses declined. For the first nine months of 2025, net loss narrowed to $3,410,700 from $5,821,067 in the prior-year period. Cash and cash equivalents were $2,517,218 at September 30, 2025, with an accumulated deficit of $205,798,707, and management states there is substantial doubt about the company’s ability to continue as a going concern.
Total assets rose to $135,370,340 from $85,409,506, driven by the March 2024 ImmunogenX acquisition and the September 30, 2025 acquisition of Grid AI Corp., which added developed technology, customer relationships, trade name intangibles and $25,796,163 of goodwill. Assets and liabilities related to ImmunogenX, including Latiglutenase and CypCel, are classified as held for sale and treated as discontinued operations. The Grid AI deal also introduced a non-controlling interest of $5,287,000 and new Series H preferred stock that is convertible into common shares subject to shareholder approval.